Radiotherapy and androgen deprivation for prostate cancer

New England Journal of Medicine

Volumn 365, Issue 14, 2011, Pages 1354-1355

  Créhange, Gilles ^a   Bolla, Michel ^b   Maingon, Philippe ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b CHU La Tronche and University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; HUMAN; INTERMEDIATE RISK PATIENT; LETTER; OVERALL SURVIVAL; PATIENT; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

EID: 80053498353     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1109225     Document Type: Letter

References (5)

1. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107-18.
2. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 2000;18:2740-6. (Pubitemid 30463557)
3. Nguyen PL, Chen MH, Beard CJ, et al. Radiation with orwithout 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys 2010;77:1046-52.
4. Valicenti RK, Bae K, Michalski J, et al. Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. Int J Radiat Oncol Biol Phys 2011;79:1323-9.
5. Lawton CA, DeSilvio M, Roach M III, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007;69:646-55. (Pubitemid 47418390)